{
    "2019-04-22": [
        [
            {
                "time": "2019-04-22",
                "original_text": "Health Care Sector Update for 04/22/2019: ISRG, AXGN, LLY, JNJ, PFE, ABT, MRK, AMGN",
                "features": {
                    "keywords": [
                        "Health Care Sector",
                        "LLY",
                        "JNJ",
                        "PFE"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-22",
                "original_text": "Eli Lilly Falls Despite Positive Phase 3 Results From Taltz Study",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Falls",
                        "Positive Phase 3",
                        "Taltz"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-04-22",
                "original_text": "Update: Eli Lilly (NYSE:LLY) Stock Gained 97% In The Last Five Years",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Stock Gained",
                        "97%",
                        "Five Years"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-22",
                "original_text": "Eli Lilly-Pfizer's Non-Opioid Painkiller Faces Safety, Efficacy Concerns",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Pfizer",
                        "Non-Opioid",
                        "Safety",
                        "Efficacy"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-04-22",
                "original_text": "Eli Lilly stock down 3.4% despite positive Phase 3 findings for Taltz",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "stock down",
                        "Phase 3",
                        "Taltz"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-04-22",
                "original_text": "Lilly Announces Positive Top-Line Results for COAST-X, a 52-Week Placebo-Controlled Study of TaltzÂ® (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Positive Top-Line",
                        "COAST-X",
                        "Taltz",
                        "Spondyloarthritis"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-22",
                "original_text": "Lilly and Avidity Biosciences Announce Licensing and Research Collaboration",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Avidity Biosciences",
                        "Licensing",
                        "Research Collaboration"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}